Search Results - "Moreau, Allison R."

Effects of Omeprazole on Plasma Levels of Raltegravir by Iwamoto, Marian, Wenning, Larissa A., Nguyen, Bach-Yen, Teppler, Hedy, Moreau, Allison R., Rhodes, Rand R., Hanley, William D., Jin, Bo, Harvey, Charlotte M., Breidinger, Sheila A., Azrolan, Neal, Farmer, H. Frank, Isaacs, Robin D., Chodakewitz, Jeffery A., Stone, Julie A., Wagner, John A.

“…Raltegravir, a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, has pH-dependent solubility. Raltegravir plasma concentration increases with…”
Get full text

First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors by Maitland, Michael L, Sachdev, Jasgit C, Sharma, Manish R, Moreno, Victor, Boni, Valentina, Kummar, Shivaani, Stringer-Reasor, Erica, Lakhani, Nehal, Moreau, Allison R, Xuan, Dawei, Li, Ray, Powell, Eric L, Jackson-Fisher, Amy, Bowers, Michelle, Alekar, Shilpa, Xin, Xiaohua, Tolcher, Anthony W, Calvo, Emiliano

“…We investigated safety, tolerability, pharmacokinetics, and antitumor activity of the protein tyrosine kinase 7 (PTK7)-targeted, auristatin-based antibody-drug…”
Get full text

Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women by Anderson, Matt S., Hanley, William D., Moreau, Allison R., Jin, Bo, Bieberdorf, Frederick A., Kost, James T., Wenning, Larissa A., Stone, Julie A., Wagner, John A., Iwamoto, Marian

“…WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Oral contraceptives are a widely prescribed means of birth control that requires the maintenance of adequate…”
Get full text

First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer by Yap, Timothy A., Elhaddad, Abdelaziz M., Grisham, Rachel N., Hamm, John Turner, Marks, Douglas Kanter, Shapiro, Geoffrey, Le Corre, Christophe, Li, Jerry, Lin, Tun Tun, Liu, Feng, Malky, Lara, Moreau, Allison R, Neumann, Heather, Juric, Dejan, Sharma, Manish

“…3010 Background: PF-07104091 is a novel CDK2-selective inhibitor under investigation in pts with selected advanced or metastatic solid tumors. We present the…”
Get full text

Abstract P5-16-06: A first-in-human phase 1/2a dose escalation/expansion study of the first-in-class CDK2/4/6 inhibitor PF-06873600 alone or with endocrine therapy in patients with breast or ovarian cancer by Yap, Timothy A., Basu, Cynthia, Goldman, Jonathan W., Gordon, Michael, Hamilton, Erika, Kelly, Adrianne, Liu, Feng, Moreau, Allison R., Neumann, Heather, Papadopoulos, Kyriakos, Rugo, Hope S., Shapiro, Geoffrey I., Vinayak, Shaveta, Zhou, Li, Jhaveri, Komal

“…Abstract Introduction: Despite initial efficacy, most patients (pts) with HR+/HER2– advanced breast cancer (BC) eventually progress on endocrine therapy (ET)…”
Get full text